Cabatit Kyle Andrei, Carandang Lara Justine, Saragpon Dianne Joyce, Minalang Khayria, Paulin John, Devanadera Mark Kevin, Daya Minerva
Department of Biochemistry, Faculty of Pharmacy, University of Santo Tomas, Philippines.
Research Center for Natural and Applied Sciences, University of Santo Tomas, Philippines.
Asian Pac J Cancer Prev. 2025 Mar 1;26(3):925-934. doi: 10.31557/APJCP.2025.26.3.925.
To evaluate the anticancer potential of Acteoside and Plantamajoside using MCF-7 cancer cell line.
In this study, the half-maximal inhibitory concentration (IC50) values of Acteoside and Plantamajoside were investigated using the Sulforhodamine B (SRB) assay. The IC50 values of both compounds were utilized in the clonogenic and scratch wound assays to assess cell survival and migration, respectively. The cells with treatments were also analyzed using the Caspase 3/7 assay to determine their capability to induce cell apoptosis. Network Pharmacology was used to evaluate their probable protein targets and pharmacological mechanisms.
Acteoside and Plantamajoside exhibited cytotoxic activity against the MCF-7 cancer cell line in vitro, with IC50 values of 134.83 μg/mL and 225.10 μg/mL, respectively. This was further supported by clonogenic assay, which showed a difference in colony formation following treatment with ACT and PMS, compared to the negative control. Specifically, ACT resulted in the formation of only 39.7% of colonies, whereas PMS formed 51.12% of colonies, indicating that these compounds impaired the cells' ability to proliferate and form colonies. Moreover, these compounds were also able to inhibit cell migration as a reduction in the migration area of the MCF-7 cell line was observed. An increase in the percentage of apoptotic cells was also noted post-treatment, which correlated with elevated Caspase 3/7 activity, indicating that these compounds may effectively induce cellular apoptosis. In silico predictions demonstrated that the compounds' anticancer effect may be attributed to their interactions with TLR, PI3K, and STAT-all are implicated in the PD-1 checkpoint pathway and PD-L1 expression in cancer.
Both Acteoside and Plantamajoside have demonstrated promising anticancer properties by inhibiting the growth and metastasis of MCF-7 cancer cell line. These compounds induce apoptosis, modulate the PD-1 checkpoint pathway, and influence PD-L1 expression, which may indicate possible molecular mechanisms for their anticancer effects.
使用MCF-7癌细胞系评估毛蕊花糖苷和大车前苷的抗癌潜力。
在本研究中,采用磺酰罗丹明B(SRB)法研究毛蕊花糖苷和大车前苷的半数抑制浓度(IC50)值。这两种化合物的IC50值分别用于克隆形成试验和划痕试验,以评估细胞存活和迁移情况。还使用Caspase 3/7试验分析经处理的细胞,以确定它们诱导细胞凋亡的能力。利用网络药理学评估它们可能的蛋白质靶点和药理机制。
毛蕊花糖苷和大车前苷在体外对MCF-7癌细胞系表现出细胞毒性活性,IC50值分别为134.83μg/mL和225.10μg/mL。克隆形成试验进一步支持了这一结果,该试验显示与阴性对照相比,用ACT和PMS处理后菌落形成存在差异。具体而言,ACT仅导致39.7%的菌落形成,而PMS形成51.12%的菌落,表明这些化合物损害了细胞增殖和形成菌落的能力。此外,这些化合物还能够抑制细胞迁移,因为观察到MCF-7细胞系的迁移面积减少。处理后还观察到凋亡细胞百分比增加,这与Caspase 3/7活性升高相关,表明这些化合物可能有效诱导细胞凋亡。计算机预测表明,这些化合物的抗癌作用可能归因于它们与TLR、PI3K和STAT的相互作用——所有这些都与癌症中的PD-1检查点途径和PD-L1表达有关。
毛蕊花糖苷和大车前苷均通过抑制MCF-7癌细胞系的生长和转移表现出有前景的抗癌特性。这些化合物诱导细胞凋亡,调节PD-1检查点途径,并影响PD-LI表达,这可能表明它们抗癌作用的可能分子机制。